Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 714% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 292.4% — good return on equity
- High dividend yield of 205.1%
Stablecoin Development Corp (NBY) is a Healthcare company operating in Pharmaceutical Preparations, listed on the AMEX , with a market capitalisation of $52 million . Key value metrics: P/E ratio 16.0, P/B ratio 163.62, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Stablecoin Development Corp — Fundamental Analysis Summary
Stablecoin Development Corp (NBY) is currently trading 714% above its Graham Number of $0.24, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 16.0x.
On financial health, NBY shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 292.4% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.67.
StockPik's composite Value Score for NBY is 55/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NBY shows earnings declining at 207%.
NBY pays a high dividend yield of 205.1%.